NewsBenzingaUCB和Biogen报告:与安慰剂相比,Dapirolizumab Pegol联合标准治疗在新型TRM-SLE中的应答率更高,并在PHOENYCS GO 3期后续分析中显示出更高的持续低疾病活动水平 UCB和Biogen报告:与安慰剂相比,Dapirolizumab Pegol联合标准治疗在新型TRM-SLE中的应答率更高,并在PHOENYCS GO 3期后续分析中显示出更高的持续低疾病活动水平 Benzinga 2026.11.09 06:56 (GMT+0) Open on Benzinga Other news AECOM Hikes Dividend, Backlog Hits Record $28 Billion Elon Musk Steps in After Jensen Huang Loses X Verification Following Nvidia Exit: ‘Blue Check Coming Back for Free on the House’ Trump Backs Howard Lutnick Amid Nvidia Row, Says Restrictions Could Have Triggered China Showdown: ‘I Understand Both Sides of It’ Nvidia Forms Board Panel for Export-Control Oversight Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free Amazon Cranks Up Its India Clean Energy Investment With Fresh $7 Billion Bet
Elon Musk Steps in After Jensen Huang Loses X Verification Following Nvidia Exit: ‘Blue Check Coming Back for Free on the House’
Trump Backs Howard Lutnick Amid Nvidia Row, Says Restrictions Could Have Triggered China Showdown: ‘I Understand Both Sides of It’
Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free